We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Molecular Breast Imaging May Provide Better Detection Than MRI for Women with Dense Breasts

By MedImaging International staff writers
Posted on 18 Jul 2012
According to a new study by Korean researchers, molecular breast imaging (MBI), also known as breast-specific gamma imaging (BSGI), may be a better option than magnetic resonance imaging (MRI) for women who have a new cancer diagnosis and dense breast tissue detected by mammography. According to their findings, MBI/BSGI and MRI had nearly the same sensitivity for the detection of additional malignant tumors, but MBI/BSGI was much less likely to be positive in benign lesions.

In their study, Dr. B.S. Kim and his colleagues, from the Mokdong Hospital, Ewha Womans University School of Medicine (Seoul, Korea), assessed 66 patients who had a new breast cancer diagnosis and a reported mammography breast density of greater than 50% with MBI/BSGI and MRI prior to surgery. Both MBI/BSGI and MRI detected disease not visualized by mammography; however, the MBI/BSGI was more accurate than MRI in determining if lesions were benign or malignant. Only 26% of the additional lesions identified by MRI were malignant compared to MBI/BSGI, where 76% of the lesions detected were malignant. This is significant for the newly diagnosed breast cancer patient since biopsy is required when imaging studies are positive. Therefore, MBI/BSGI could have led to a large decrease in the number of unnecessary biopsies for women in this trial. According to Dr. Kim, “The results of this study suggest that MBI/BSGI could play a crucial role as an adjunctive imaging modality which can be used to evaluate breast cancer patients with dense breasts.”

Dilon Diagnostics (Newport News, VA, USA), a brand of Dilon Technologies, Inc., cornerstone product, the Dilon 6800, is a high-resolution, small field-of-view gamma camera, optimized to perform MBI/BSGI, a molecular breast imaging procedure that images the metabolic activity of breast lesions through radiotracer uptake.

The study’s findings were published February 26, 2012, in the journal Annals of Nuclear Medicine.

Related Links:

Ewha Womans University School of Medicine
Dilon Diagnostics


New
Half Apron
Demi
Ultrasound Imaging System
P12 Elite
Biopsy Software
Affirm® Contrast
Digital Radiographic System
OMNERA 300M

Channels

Ultrasound

view channel
Image: The new implantable device for chronic pain management is small and flexible (Photo courtesy of The Zhou Lab at USC)

Wireless Chronic Pain Management Device to Reduce Need for Painkillers and Surgery

Chronic pain affects millions of people globally, often leading to long-term disability and dependence on opioid medications, which carry significant risks of side effects and addiction.... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.